x
Filter:
Filters applied
- Melanoma
- Rapid CommunicationRemove Rapid Communication filter
Publication Date
Please choose a date range between 2015 and 2018.
Author
- Amos, Christopher I1
- Bahrami, Armita1
- Barnhill, Raymond L1
- Bassett, Roland L1
- Bremer, Edwin1
- Chu, Ruiyin1
- Cormier, Janice N1
- Cornelius, Lynn A1
- Council, M Laurin1
- Dang, Yifang1
- Davies, Michael A1
- Dummer, Reinhard1
- Dusza, Stephen W1
- Easton, John1
- Fan, Yiping1
- Fang, Shenying1
- Fields, Ryan C1
- Gagel, Andrew1
- Gershenwald, Jeffrey E1
- Hai, Pengfei1
- Halpern, Allan C1
- Harris, John E1
- Haydu, Lauren E1
- He, Yuan1
- Helfrich, Wijnand1
Melanoma
8 Results
- Letter to the EditorOpen Archive
Automated Dermatological Diagnosis: Hype or Reality?
Journal of Investigative DermatologyVol. 138Issue 10p2277–2279Published online: June 1, 2018- Cristian Navarrete-Dechent
- Stephen W. Dusza
- Konstantinos Liopyris
- Ashfaq A. Marghoob
- Allan C. Halpern
- Michael A. Marchetti
Cited in Scopus: 57In this issue of the Journal of Investigative Dermatology, Han et al. (2018) have made a landmark contribution to the application of artificial intelligence (AI) in dermatologic diagnosis. Although previous studies have reported that computer algorithms can successfully diagnose skin cancer from medical images with human equivalency (Esteva et al., 2017; Ferris et al., 2015; Marchetti et al., 2018; Menzies et al., 2005), Han et al. have made their computer algorithm publicly available for external testing. - Letter to the EditorOpen Archive
Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes
Journal of Investigative DermatologyVol. 137Issue 8p1792–1795Published online: April 22, 2017- Shenying Fang
- Yuling Wang
- Yifang Dang
- Andrew Gagel
- Merrick I. Ross
- Jeffrey E. Gershenwald
- and others
Cited in Scopus: 31Obesity is a known risk factor for cancer development (Arnold et al., 2016; Basen-Engquist and Chang, 2011; Renehan et al., 2015) and death (Calle et al., 2003). Obesity has been associated with an increased risk of developing melanoma in men (Sergentanis et al., 2013) and with thicker primary melanomas (Skowron et al., 2015). The inflammatory adipokine leptin promotes melanoma progression in mice (Amjadi et al., 2011; Brandon et al., 2009; Gogas et al., 2008); elevated leptin levels may predict melanoma sentinel node metastasis (Oba et al., 2016). - Letter to the EditorOpen Archive
Noninvasive Determination of Melanoma Depth using a Handheld Photoacoustic Probe
Journal of Investigative DermatologyVol. 137Issue 6p1370–1372Published online: February 2, 2017- Yong Zhou
- Shivani V. Tripathi
- Ilana Rosman
- Jun Ma
- Pengfei Hai
- Gerald P. Linette
- and others
Cited in Scopus: 45When a clinically suspicious pigmented lesion is biopsied and histologic examination shows melanoma, tumor depth, or Breslow’s depth (BD), is the key parameter that both determines surgical margins for definitive excision and serves as an indication to perform sentinel lymph node biopsy (Smith and MacNeil, 2011). Optimally, BD is measured during an initial excisional biopsy that includes the entire lesion. However, in many cases an incisional biopsy is performed that takes a sample of only a portion of the tumor, possibly resulting in an inaccurate measurement (Guitera and Menzies, 2011; Sellheyer et al., 2010). - Letter to the EditorOpen Archive
CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice
Journal of Investigative DermatologyVol. 137Issue 4p982–985Published online: January 23, 2017- Jillian M. Richmond
- Elizabeth Masterjohn
- Ruiyin Chu
- Jennifer Tedstone
- Michele E. Youd
- John E. Harris
Cited in Scopus: 49Vitiligo is a disfiguring skin disease in which melanocytes with intrinsic abnormalities are targeted and destroyed by autoreactive CD8+ T cells in the epidermis, resulting in patchy depigmentation (Palermo et al., 2001; van den Boorn et al., 2009, and reviewed in Richmond et al., 2013). Although it is one of the most common autoimmune diseases, affecting 1% of the population worldwide, there are no Food and Drug Administration-approved treatments. Previous work from our lab has shown that CD8+ T-cell recruitment to the skin in a mouse model of vitiligo is dependent on IFNγ (Harris et al., 2012) and the downstream CXCR3 chemokine system (Rashighi et al., 2014). - Letter to the EditorOpen Access
Consensus of Melanoma Gene Expression Subtypes Converges on Biological Entities
Journal of Investigative DermatologyVol. 136Issue 12p2502–2505Published online: June 23, 2016- Martin Lauss
- Jeremie Nsengimana
- Johan Staaf
- Julia Newton-Bishop
- Göran Jönsson
Cited in Scopus: 20Identification of recurrent mutation in the BRAF oncogene in melanoma has led to the development of highly selective kinase inhibitors (Larkin et al., 2014). Although dramatic treatment responses are initially observed, responses are rarely durable. The mutational classification based on BRAF, NRAS, and NF1 mutations that has been established, however, is nonoverlapping with classification derived from gene expression profiling (The Cancer Genome Atlas Network [TCGA], 2015; Jönsson et al., 2010). - Letter to the EditorOpen Access
Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi
Journal of Investigative DermatologyVol. 136Issue 1p339–342Published in issue: January, 2016- Yiping Fan
- Seungjae Lee
- Gang Wu
- John Easton
- Donald Yergeau
- Reinhard Dummer
- and others
Cited in Scopus: 30Telomeres are tandem repeats of the noncoding DNA structures at the end of human chromosomes that protect the coding DNA and the integrity of the genome (Blackburn, 1991). The ability to sustain telomere length confers unlimited proliferative capacity to cancer cells. In most cancers telomere length is maintained by the activity of the enzyme telomerase (Kim et al., 1994), whose catalytic subunit is encoded by the telomerase reverse transcriptase (TERT) gene. However, until recently, the underlying mechanisms for telomerase activation in cancer cells were largely unknown. - Letter to the EditorOpen Archive
Validity of Self-Reported Psoriasis in a General Population: The HUNT Study, Norway
Journal of Investigative DermatologyVol. 136Issue 1p323–325Published in issue: January, 2016- Ellen Heilmann Modalsli
- Ingrid Snekvik
- Bjørn Olav Åsvold
- Pål Richard Romundstad
- Luigi Naldi
- Marit Saunes
Cited in Scopus: 28A high prevalence of psoriasis has been reported in Norway, ranging from 4.8% to 11.8% (Bo et al., 2008; Danielsen et al., 2013; Kavli et al., 1985; Parisi et al., 2013). Prevalence estimates depend crucially on the validity of questionnaires (Jagou et al., 2006; Kurd and Gelfand, 2009; Lima et al., 2013; Plunkett et al., 1999; Rea et al., 1976; Wolkenstein et al., 2009). We aimed to validate self-reported psoriasis in a large population-based study in Norway using clinical skin examination performed by dermatologists as the gold standard and also to estimate the validation-based prevalence of psoriasis in a general Norwegian population. - Letter to the EditorOpen Archive
Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5
Journal of Investigative DermatologyVol. 136Issue 2p541–544Published online: November 30, 2015- Yuan He
- Djoke Hendriks
- Robert van Ginkel
- Douwe Samplonius
- Edwin Bremer
- Wijnand Helfrich
Cited in Scopus: 17Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an immune effector protein that induces apoptosis in virus-infected and cancer cells by activating death receptor-4 (DR4) and/or death receptor-5 (DR5) without deleterious activity toward DR4/DR5-expressing normal cells (Ashkenazi et al., 2008). Consequently, DR4/DR5 agonists are promising anticancer agents. Treatment with “first-generation” DR4/DR5-targeted therapeutics, such as recombinant human soluble tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) and agonistic DR4/DR5 antibodies, was well tolerated but had disappointing clinical activity (Ashkenazi, 2015).